Skip to main content
Top

Cancer Chemotherapy and Pharmacology

Issue 3/2005

Content (13 Articles)

Original Article

Control of Atm−/− thymic lymphoma cell proliferation in vitro and in vivo by dexamethasone

Xianghong Kuang, Mingshan Yan, Na Liu, Virginia L. Scofield, Wenan Qiang, Jodi Cahill, Williams S. Lynn, Paul K. Y. Wong

Original Article

Incorporation of OSI-7836 into DNA of Calu-6 and H460 xenograft tumors

Frank Richardson, Chris Black, Katherine Richardson, April Franks, Edward Wells, Susan Karimi, Gina Sennello, Karen Hart, Denny Meyer, David Emerson, Eric Brown, Jeremy LeRay, Christy Nilsson, Blake Tomkinson, Raymond Bendele

Original Article

Magnesium and potassium homeostasis during cisplatin treatment

H. Lajer, M. Kristensen, H. H. Hansen, S. Christensen, Ten Jonassen, G. Daugaard

Original Article

Population pharmacokinetic analysis of 17-(allylamino)-17-demethoxygeldanamycin (17AAG) in adult patients with advanced malignancies

Xueyu Chen, Robert R. Bies, Ramesh K. Ramanathan, Eleanor G. Zuhowski, Donald L. Trump, Merrill J. Egorin

Original Article

Particular cutaneous side effects with etoposide-containing courses: is VP16 or etoposide phosphate responsible?

Katel Marigny, Fabienne Aubin, Gwenola Burgot, Edouard Le Gall, Virginie Gandemer

Original Article

Phase I study of an oral formulation of irinotecan administered daily for 14 days every 3 weeks in patients with advanced solid tumours

Nadja E. Schoemaker, I. E. L. M. Kuppens, Wim W. Ten Bokkel Huinink, Patricia Lefebvre, Jos H. Beijnen, Sylvie Assadourian, Ger-Jan Sanderink, Jan H. M. Schellens

Original Article

Description of paclitaxel resistance-associated genes in ovarian and breast cancer cell lines

Zhenfeng Duan, Diana E. Lamendola, Yifei Duan, Rushdia Z. Yusuf, Michael V. Seiden

Clinical Trial Report

A phase IB clinical and pharmacokinetic study of the angiogenesis inhibitor SU5416 and paclitaxel in recurrent or metastatic carcinoma of the head and neck

Matthew M. Cooney, Kou-Yi Tserng, Vinit Makar, R. Jeff McPeak, Stephen T. Ingalls, Afshin Dowlati, Beth Overmoyer, Keith McCrae, Pamela Ksenich, Pierre Lavertu, Percy Ivy, Charles L. Hoppel, Scot Remick

Short Communication

Oxaliplatin activity in head and neck cancer cell lines

Magali Espinosa, Moises Martinez, José Luis Aguilar, Aída Mota, Jaime G. De la Garza, Vilma Maldonado, Jorge Meléndez-Zajgla

Webinar | 19-02-2024 | 17:30 (CET)

Keynote webinar | Spotlight on antibody–drug conjugates in cancer

Antibody–drug conjugates (ADCs) are novel agents that have shown promise across multiple tumor types. Explore the current landscape of ADCs in breast and lung cancer with our experts, and gain insights into the mechanism of action, key clinical trials data, existing challenges, and future directions.

Dr. Véronique Diéras
Prof. Fabrice Barlesi
Developed by: Springer Medicine